Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical benefit and tolerability of adalimumab, a
fully human monoclonal antibody to tumor necrosis factor α (TNF- α), in patients with
ulcerative colitis (UC) naive to treatment with biologics.